Clinical Trials Browser

Terminated × Recurrence × Bortezomib × Clear all

NCT00464178 2022-07-20

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled 5 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Phase 3 Terminated

269 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT01504477 2020-03-16

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Phase 1/2 Terminated

6 enrolled 8 charts

Gastrointestinal

Recurrence, Colorectal Neoplasms

NCT02535806 2019-08-13

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Phase 2 Terminated

2 enrolled 11 charts

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01470131 2018-12-19

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Phase 3 Terminated

Multiple Myeloma, Recurrence

NCT01672736 2018-09-13

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Phase 1/2 Terminated

19 enrolled 10 charts

Multiple Myeloma, Recurrence

NCT01695330 2017-01-16

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Phase 2 Terminated

5 enrolled 6 charts

Multiple Myeloma, Recurrence

NCT00671112 2015-10-28

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1 Terminated

DermatologicLymphoidOther hematologic neoplasm

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT00441168 2014-03-21

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Phase 2 Terminated

30 enrolled 14 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT00136591 2010-10-26

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Phase 2 Terminated

Lymphoma, Follicular, Recurrence

NCT00352742 2008-10-28

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

Phase 1/2 Terminated

Multiple Myeloma, Recurrence

NCT00148018 2008-07-10

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

Phase 2 Terminated

Hodgkin Disease, Lymphoma, Recurrence